REFERENCES
- Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou X H, Ny L, Andersson K E, Kehrel B, Offermanns S, Fassler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. Embo J 1999; 18: 37–48, [PUBMED], [INFOTRIEVE], [CSA]
- Baumgartner H R, Born G V. Effects of 5-hydroxytryptamine on platelet aggregation. Nature 1968; 218: 137–141, [PUBMED], [INFOTRIEVE]
- Bennett J S. Platelet-fibrinogen interactions. Ann NY Acad Sci 2001; 936: 340–354, [PUBMED], [INFOTRIEVE]
- Bierl C, Voetsch B, Jin R C, Handy D E, Loscalzo J. Determinants of human plasma glutathione peroxidase (GPx-3) expression. J Biol Chem 2004; 279: 26839–26845, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bredt D S, Snyder S H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 682–685, [PUBMED], [INFOTRIEVE], [CSA]
- Cheng Y, Austin S C, Rocca B, Koller B H, Coffman T M, Grosser T, Lawson J A, FitzGerald G A. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539–541, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Crane M S, Ollosson R, Moore K P, Rossi A G, Megson I L. Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function. J Biol Chem 2002; 277: 46858–46863, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Davenpeck K L, Gauthier T W, Lefer A M. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 1994; 107: 1050–1058, [PUBMED], [INFOTRIEVE], [CSA]
- de Belder A J, MacAllister R, Radomski M W, Moncada S, Vallance P J. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994; 28: 691–694, [PUBMED], [INFOTRIEVE], [CSA]
- Dogru-Abbasoglu S, Kanbagli O, Bulur H, Babalik E, Ozturk S, Aykac-Toker G, Uysal M. Lipid peroxides and antioxidant status in serum of patients with angiographically defined coronary atherosclerosis. Clin Biochem 1999; 32: 671–672, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Eberhardt R, Loscalzo J. Nitric Oxide in Atherosclerosis. Nitric Oxide and the Cardiovascular System. 2000; 273–295
- Ervin A L, Peerschke E I. Platelet activation by sustained exposure to low-dose plasmin. Blood Coagul Fibrinolysis 2001; 12: 415–425, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Freedman J E, Loscalzo J, Barnard M R, Alpert C, Keaney J F, Michelson A D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350–356, [PUBMED], [INFOTRIEVE], [CSA]
- Freedman J E, Loscalzo J, Benoit S E, Valeri C R, Barnard M R, Michelson A D. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 1996; 97: 979–987, [PUBMED], [INFOTRIEVE], [CSA]
- Furchgott R F, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373–376, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gayle R B, 3rd, Maliszewski C R, Gimpel S D, Schoenborn M A, Caspary R G, Richards C, Brasel K, Price V, Drosopoulos J H, Islam N, Alyonycheva T N, Broekman M J, Marcus A J. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 1998; 101: 1851–1859, [PUBMED], [INFOTRIEVE], [CSA]
- Giustarini D, Milzani A, Colombo R, Dalle-Donne I, Rossi R. Nitric oxide and S-nitrosothiols in human blood. Clin Chim Acta 2003; 330: 85–98, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gorman R R, Bunting S, Miller O V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977; 13: 377–388, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gouin I, Lecompte T, Morel M C, Lebrazi J, Modderman P W, Kaplan C, Samama M M. In vitro effect of plasmin on human platelet function in plasma: inhibition of aggregation caused by fibrinogenolysis. Circulation 1992; 85: 935–941, [PUBMED], [INFOTRIEVE]
- Handagama P J, Bainton D F. Incorporation of a circulating protein into alpha granules of megakaryocytes. Blood Cells 1989; 15: 59–72, [PUBMED], [INFOTRIEVE]
- Hogg N. The biochemistry and physiology of S-nitrosothiols. Annu Rev Pharmacol Toxicol 2002; 42: 585–600, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994; 225: 21–27, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ignarro L J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65: 1–21, [PUBMED], [INFOTRIEVE]
- Ishii-Watabe A, Uchida E, Mizuguchi H, Hayakawa T. On the mechanism of plasmin-induced platelet aggregation: implications of the dual role of granule ADP. Biochem Pharmacol 2000; 59: 1345–1355, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kaczmarek E, Koziak K, Sevigny J, Siegel J B, Anrather J, Beaudoin A R, Bach F H, Robson S C. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996; 271: 33116–33122, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, Vavva F, Brand N, Michelson A, Trolliet M, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol 1999; 19: 2017–2023, [PUBMED], [INFOTRIEVE], [CSA]
- Krumenacker J S, Hanafy K A, Murad F. Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull 2004; 62: 505–515, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lim H, Dey S K. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002; 143: 3207–3210, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Liu Z, Rudd M A, Freedman J E, Loscalzo J. S-Transnitrosation reactions are involved in the metabolic fate and biological actions of nitric oxide. J Pharmacol Exp Ther 1998; 284: 526–534, [PUBMED], [INFOTRIEVE], [CSA]
- Ludwig R J, Schultz J E, Boehncke W H, Podda M, Tandi C, Krombach F, Baatz H, Kaufmann R, von Andrian U H, Zollner T M. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004; 122: 830–836, [PUBMED], [CROSSREF]
- Marcus A J, Broekman M J, Drosopoulos J H, Islam N, Alyonycheva T N, Safier L B, Hajjar K A, Posnett D N, Schoenborn M A, Schooley K A, Gayle R B, Maliszewski C R. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351–1360, [PUBMED], [INFOTRIEVE], [CSA]
- Marletta M A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994; 78: 927–930, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Marley R, Patel R P, Orie N, Ceaser E, Darley-Usmar V, Moore K. Formation of nanomolar concentrations of S-nitroso-albumin in human plasma by nitric oxide. Free Radic Biol Med 2001; 31: 688–696, [PUBMED], [CROSSREF], [CSA]
- Marriott H M, Ali F, Read R C, Mitchell T J, Whyte M K, Dockrell D H. Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. Faseb J 2004; 18: 1126–1128, [PUBMED]
- Matrisian L M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121–125, [PUBMED], [CROSSREF]
- Mendelsohn M E, O'Neill S, George D, Loscalzo J. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 1990; 265: 19028–19034, [PUBMED]
- Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–665, [PUBMED]
- Moncada S, Higgs E A, Vane J R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977; 1: 18–20, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Moreau V H, Castilho R F, Ferreira S T, Carvalho-Alves P C. Oxidative damage to sarcoplasmic reticulum Ca2+-ATPase AT submicromolar iron concentrations: evidence for metal-catalyzed oxidation. Free Radic Biol Med 1998; 25: 554–560, [PUBMED], [CROSSREF], [CSA]
- Murad F, Mittal C K, Arnold W P, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res 1978; 9: 145–158, [PUBMED]
- Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678–682, [PUBMED], [CROSSREF]
- Murohara T, Parkinson S J, Waldman S A, Lefer A M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets: role of protein kinase C. Arterioscler Thromb Vasc Biol 1995; 15: 2068–2075, [PUBMED], [CSA]
- Muzakova V, Kandar R, Vojtisek P, Skalicky J, Cervinkova Z. Selective antioxidant enzymes during ischemia/reperfusion in myocardial infarction. Physiol Res 2000; 49: 315–322, [PUBMED], [CSA]
- Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, Narumiya S. cDNA cloning of a mouse prostacyclin receptor: multiple signaling pathways and expression in thymic medulla. J Biol Chem 1994; 269: 9986–9992, [PUBMED]
- Nathan C, Xie Q W. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269: 13725–13728, [PUBMED]
- Palmer R M, Ferrige A G, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–526, [PUBMED], [CROSSREF]
- Pariente J A, Camello C, Camello P J, Salido G M. Release of calcium from mitochondrial and nonmitochondrial intracellular stores in mouse pancreatic acinar cells by hydrogen peroxide. J Membr Biol 2001; 179: 27–35, [PUBMED], [CROSSREF], [CSA]
- Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404–414, [PUBMED], [CSA]
- Pignatelli P, Pulcinelli F M, Lenti L, Gazzaniga P P, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91: 484–490, [PUBMED], [CSA]
- Pinsky D J, Broekman M J, Peschon J J, Stocking K L, Fujita T, Ramasamy R, Connolly E S, Jr, Huang J, Kiss S, Zhang Y, Choudhri T F, McTaggart R A, Liao H, Drosopoulos J H, Price V L, Marcus A J, Maliszewski C R. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002; 109: 1031–1040, [PUBMED], [CROSSREF], [CSA]
- Porter M, Pearson D J, Suarez-Mendez V J, Blann A D. Plasma, platelet and erythrocyte glutathione peroxidases as risk factors in ischaemic heart disease in man. Clin Sci (Lond) 1992; 83: 343–345
- Quinton T M, Kim S, Derian C K, Jin J, Kunapuli S P. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004; 279: 18434–18439, [PUBMED]
- Rabhi-Sabile S, de Romeuf C, Pidard D. On the mechanism of plasmin-induced aggregation of human platelets: implication of secreted von Willebrand factor. Thromb Haemost 1998; 79: 1191–1198, [PUBMED], [CSA]
- Rassaf T, Kleinbongard P, Preik M, Dejam A, Gharini P, Lauer T, Erckenbrecht J, Duschin A, Schulz R, Heusch G, Feelisch M, Kelm M. Plasma nitrosothiols contribute to the systemic vasodilator effects of intravenously applied NO: experimental and clinical study on the fate of NO in human blood. Circ Res 2002; 91: 470–477, [PUBMED], [CROSSREF]
- Redondo P C, Salido G M, Pariente J A, Rosado J A. Dual effect of hydrogen peroxide on store-mediated calcium entry in human platelets. Biochem Pharmacol 2004; 67: 1065–1076, [PUBMED], [CROSSREF]
- Redondo P C, Salido G M, Rosado J A, Pariente J A. Effect of hydrogen peroxide on Ca2+ mobilisation in human platelets through sulphydryl oxidation dependent and independent mechanisms. Biochem Pharmacol 2004; 67: 491–502, [PUBMED], [CROSSREF]
- Reed G L. Platelet secretion. Platelets, A D Michelson. Elsevier Science, San Diego 2002; 181–195
- Reed G L, Fitzgerald M L, Polgar J. Molecular mechanisms of platelet exocytosis: insights into the “secrete” life of thrombocytes. Blood 2000; 96: 3334–3342, [PUBMED], [CSA]
- Schafer A I, Zavoico G B, Loscalzo J, Maas A K. Synergistic inhibition of platelet activation by plasmin and prostaglandin I2. Blood 1987; 69: 1504–1507, [PUBMED]
- Scharfstein J S, Keaney J F, Jr, Slivka A, Welch G N, Vita J A, Stamler J S, Loscalzo J. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 1994; 94: 1432–1439, [PUBMED], [CSA]
- Shah C M, Locke I C, Chowdrey H S, Gordge M P. Rapid S-nitrosothiol metabolism by platelets and megakaryocytes. Biochem Soc Trans 2003; 31: 1450–1452, [PUBMED]
- Simon D I, Stamler J S, Jaraki O, Keaney J F, Osborne J A, Francis S A, Singel D J, Loscalzo J. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 1993; 13: 791–799, [PUBMED]
- Stamler J S, Simon D I, Jaraki O, Osborne J A, Francis S, Mullins M, Singel D, Loscalzo J. S-Nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. Proc Natl Acad Sci USA 1992; 89: 8087–8091, [PUBMED], [CSA]
- Stamler J S, Singel D J, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898–1902, [PUBMED]
- Stamler J S, Vaughan D E, Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. Circ Res 1989; 65: 796–804, [PUBMED], [CSA]
- Tateson J E, Moncada S, Vane J R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389–397, [PUBMED], [CROSSREF]
- van Gorp R M, Feijge M A, Vuist W M, Rook M B, Heemskerk J W. Irregular spiking in free calcium concentration in single, human platelets. Regulation by modulation of the inositol trisphosphate receptors. Eur J Biochem 2002; 269: 1543–1552, [PUBMED], [CROSSREF]
- Wang G R, Zhu Y, Halushka P V, Lincoln T M, Mendelsohn M E. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 1998; 95: 4888–4893, [PUBMED], [CROSSREF], [CSA]
- Wang T F, Guidotti G. CD39 is an ecto-(Ca2+, Mg2+)-apyrase. J Biol Chem 1996; 271: 9898–9901, [PUBMED], [CROSSREF]
- Wang T F, Ou Y, Guidotti G. The transmembrane domains of ectoapyrase (CD39) affect its enzymatic activity and quaternary structure. J Biol Chem 1998; 273: 24814–24821, [PUBMED], [CROSSREF]
- Weksler B B. Antiplatelet agents in stroke prevention. Combination therapy: present and future. Cerebrovasc Dis 2000; 10(Suppl 5)41–48, [PUBMED], [CROSSREF]
- Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002; 106: 2397–2403, [PUBMED], [CROSSREF]
- Zai A, Rudd M A, Scribner A W, Loscalzo J. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest 1999; 103: 393–399, [PUBMED], [CSA]
- Zhou Q, Hellermann G R, Solomonson L P. Nitric oxide release from resting human platelets. Thromb Res 1995; 77: 87–96, [PUBMED], [CROSSREF], [CSA]